NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY): Reassessing Valuation After Encouraging New Breast Cancer Data for Zovegalisib
Relay Therapeutics (RLAY) just put fresh clinical data for its PI3Kα inhibitor zovegalisib in the spotlight at the San Antonio Breast Cancer Symposium, and the update helps clarify how the stock’s story is evolving.
See our latest analysis for Relay Therapeutics.
That backdrop helps explain why, even after a 5.31% one day pullback to $8.03, Relay’s 30 day share price return is 23.35% and its year to date share price return sits at 86.74%. The 3 year total shareholder return of negative 47.03%...